Skip to main content
YIFAN PHARMACEUTICAL CO.,LTD logo

YIFAN PHARMACEUTICAL CO.,LTD — Investor Relations & Filings

Ticker · 002019 ISIN · CNE000001K65 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,499 across all filing types
Latest filing 2021-07-12 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002019

About YIFAN PHARMACEUTICAL CO.,LTD

https://www.yifanyy.com

Yifan Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and commercialization of innovative biologics, specialty small molecules, and traditional Chinese medicine. The company maintains a diverse product portfolio, notably featuring Ryzneuta (efbemalenograstim alfa), a long-acting recombinant human granulocyte colony-stimulating factor used to treat chemotherapy-induced neutropenia. It is also recognized as a major global supplier of Vitamin B5 (D-calcium pantothenate). Operating with a global perspective, the firm manages integrated R&D and production platforms that adhere to international quality standards. Its core activities span drug discovery, clinical development, and large-scale manufacturing, with a strategic emphasis on therapeutic areas such as oncology, hematology, and dermatology.

Recent filings

Filing Released Lang Actions
2021年半年度业绩预告
Regulatory Filings Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2021, explicitly stating it is a preliminary estimate by the company's finance department and not audited by a registered accountant. It provides expected profit figures and percentage changes compared to the previous year but does not contain actual audited financial statements or detailed financial data. The document is short (708 characters) and serves as an announcement of expected results rather than a full interim or quarterly report. According to the rules, such preliminary performance forecasts without substantive financial data should be classified as Regulatory Filings (RNS), as it does not meet the criteria for an Interim/Quarterly Report (IR).
2021-07-12 Chinese
关于部分限制性股票回购注销完成的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement regarding the completion of a repurchase and cancellation of restricted shares under a 2019 restricted stock incentive plan. It details the number of shares repurchased, the reasons for repurchase, the price, the impact on share capital, and related board approvals. It is a formal disclosure about a share repurchase and capital reduction event, not a financial report or earnings release. The content fits the category of a Transaction in Own Shares (POS), which covers company buybacks or cancellations of its own shares. The document length is sufficient and contains detailed information about the transaction, confirming it is not a mere announcement of a report publication or a regulatory filing. Therefore, the appropriate classification is POS with high confidence.
2021-06-28 Chinese
关于2019年限制性股票激励计划首次授予部分第二个解除限售期解除限售条件成就的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the achievement of the second unlocking condition for the 2019 restricted stock incentive plan's first grant portion by Yifan Pharmaceutical Co., Ltd. It details the number of shares eligible for unlocking, the number of incentive recipients, the conditions met, and includes legal and independent financial advisor opinions. The document is a formal announcement about the status of a stock incentive plan and the unlocking of restricted shares, not a full report or financial statement. It is not an annual report, audit report, or management report. It is also not a proxy solicitation or voting result announcement. The content focuses on stock incentive plan unlocking conditions and related approvals, which fits best under Regulatory Filings (RNS) as it is a regulatory announcement about stock incentive plan progress and compliance. The document length is over 13,000 characters, so it is not a brief report publication announcement. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-06-24 Chinese
06.25：上海天衍禾律师事务所关于亿帆医药股份有限公司2019年限制性股票激励计划首次授予的限制性股票第二次解锁、部分限制性股票回购注销相关事项之法律意见书
Board/Management Information Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the implementation and legal compliance of a company's 2019 restricted stock incentive plan, specifically about the second unlocking and partial repurchase and cancellation of restricted stocks. It extensively discusses the approval process, board and shareholder meetings, performance conditions, and legal compliance related to the stock incentive plan. There is no indication that this is a full annual or interim financial report, earnings release, or a regulatory filing announcement. The document is not a transcript, nor a capital update or dividend notice. It is a detailed legal opinion related to management decisions and corporate governance matters concerning stock incentives. Therefore, it fits best under the category of Board/Management Information (MANG), which includes announcements of changes or decisions by the company's board or senior management related to corporate governance and management actions.
2021-06-24 Chinese
第七届监事会第十七次（临时）会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 亿帆医药股份有限公司 regarding decisions made in a specific meeting. It details voting results on stock incentive plan matters and stock repurchase related to restricted stock. The document is an official announcement of board/committee decisions rather than a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a regulatory filing or proxy solicitation. The content fits best under Board/Management Information (MANG) as it relates to internal governance decisions and board resolutions.
2021-06-24 Chinese
06.25：监事会关于2019年限制性股票激励计划首次授予部分第二个解除限售期可解除限售激励对象名单的核查意见
Regulatory Filings Classification · 95% confidence The document is a formal announcement from the supervisory board regarding the verification of the list of incentive recipients eligible for the second release period of restricted stock under the company's 2019 restricted stock incentive plan. It includes legal references, compliance checks, and confirmation of eligibility for stock release. The document is short (1081 characters) and serves as an official announcement rather than a full report or detailed financial statement. It does not contain financial data or detailed management discussion but is a regulatory announcement related to stock incentive plan compliance and release. Therefore, it fits best under Regulatory Filings (RNS) as a compliance and verification announcement rather than a full report or financial disclosure.
2021-06-24 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.